Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers
Frontiers in Immunology · 24.03.2026 · 17
DOI: 10.3389/fimmu.2026.1784546 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Frontiers in Immunology, online erschienen am 24.03.2026. Verfasst von Anthony J Iacovelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, CA, United States. Hauptthemen laut MEDLINE: Immunoglobulin Fc Fragments, Membrane Proteins, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech.
Abstract (Originalsprache)
Background
Dendritic cells play a critical role in immunity. Fms-related tyrosine kinase 3 ligand (FLT3L) is a cytokine that can promote the expansion and differentiation of bone marrow dendritic cells (DC) progenitors. RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC.
Methods
This Phase Ia trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7497987 in healthy volunteers. Forty-four participants received RO7497987 as a single ascending dose (SAD, 0.7–70 mg) or multiple ascending doses (MAD, 7 or 21 mg, 21 days apart).
Results
RO7497987 was safe and well-tolerated at all doses. The most common treatment-related adverse events (AE) were Grade 1 myalgia, headache, and lymphadenopathy, all of which resolved spontaneously. There were no Grade ≥ 3 AEs, serious AEs, or dose-limiting adverse events. Pharmacokinetic analysis showed dose-dependent increases in FLT3L-Fc C max and AUC inf with no accumulation in the MAD cohorts. RO7497987 administration resulted in dose-dependent expansion of monocytes, as well as expansion of all major DC subsets, including conventional and plasmacytoid DC, which was sustained with multiple doses.
Conclusion
These findings aid the design of dosing regimens of RO7497987 as an immunomodulatory agent. Clinical trial registration https://www.isrctn.com/ISRCTN92655801 , identifier ISRCTN92655801.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, CA, United States.
Förderung
- Genentech
Zitieren
APA
Iacovelli, A. J., Sanjabi, S., Monemi, S., Amitai, A., Decalf, J., Moussion, C., Liao, M. Z., Rao, G. K., Getz, J., & Mancuso, M. R. (2026). Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1784546
Vancouver
Iacovelli AJ, Sanjabi S, Monemi S, Amitai A, Decalf J, Moussion C, et al. Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1784546
BibTeX
@article{Iacovelli2026,
author = {Iacovelli, Anthony J and Sanjabi, Shomyseh and Monemi, Sharareh and Amitai, Assaf and Decalf, Jérémie and Moussion, Christine and Liao, Michael Z and Rao, Gautham K and Getz, Jennifer and Mancuso, Michael R},
title = {Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1784546}
}
EUVIMED